Kura Oncology (NASDAQ: KURA) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Kura Oncology to related companies based on the strength of its institutional ownership, dividends, profitability, risk, earnings, analyst recommendations and valuation.

Institutional and Insider Ownership

64.3% of Kura Oncology shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 21.8% of Kura Oncology shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Kura Oncology and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Kura Oncology N/A -$27.56 million -10.32
Kura Oncology Competitors $284.49 million $34.10 million 60.05

Kura Oncology’s peers have higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Kura Oncology and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kura Oncology N/A -53.40% -44.08%
Kura Oncology Competitors -5,458.31% -208.20% -37.91%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Kura Oncology and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology 0 0 6 0 3.00
Kura Oncology Competitors 888 3278 11777 235 2.70

Kura Oncology presently has a consensus target price of $18.30, indicating a potential upside of 14.38%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.29%. Given Kura Oncology’s peers higher probable upside, analysts plainly believe Kura Oncology has less favorable growth aspects than its peers.

Kura Oncology Company Profile

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with Analyst Ratings Network's FREE daily email newsletter.